Use of a peptide or pharmaceutical composition comprising leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid for the reduction of beta-amyloid protein, modulating app processing, modulating activity of app secretases, treatment of beta-amyloid protein diseases and the treatment of Alzheimer's disease.
|
10. A method of modulating app processing comprising administration of a peptide leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid to a mammal in need of app modulation.
11. A method of modulating app secretase comprising administration of a peptide leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid to a mammal in need of app secretase modulation.
2. A method of treating a beta-amyloid protein disease comprising administration of a peptide leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid to a mammal suffering from a beta-amyloid protein disease.
1. A method of reducing beta-amyloid protein Aβ) in vivo comprising administration of a peptide leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid to a mammal suffering from accumulation of beta-amyloid protein.
6. A method of treating a beta-amyloid protein disease comprising administration of a pharmaceutical composition to a mammal suffering from a beta-amyloid protein disease wherein the pharmaceutical composition comprises peptide leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid.
5. A method of reducing beta-amyloid protein Aβ) in vivo comprising administration of a pharmaceutical composition to a mammal suffering from accumulation of beta-amyloid protein, wherein the pharmaceutical composition comprises a peptide leu-Ala-Phe-Val-leu-Arg-Lys-amide having at least one D amino acid.
3. The method of
7. The method of
9. The method of
15. The method
16. The method
17. The method
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This application is a continuation-in-part of U.S. application Ser. No. 11/732,226 filed Apr. 2, 2007 now U.S. Pat. No. 7,759,311 which is a divisional of U.S. application Ser. No. 11/016,706 filed Dec. 16, 2004 now U.S. Pat. No. 7,384,910 which is a continuation-in-part of U.S. patent application Ser. No. 09/962,955 filed Sep. 24, 2001 now U.S. Pat. No. 6,933,280 which is a continuation-in-part of U.S. patent application Ser. No. 09/938,275 filed Aug. 22, 2001, now U.S. Pat. No. 7,314,724 which is a continuation of U.S. patent application Ser. No. 08/947,057 filed Oct. 8, 1997 now abandoned; This application also claims priority to U.S. Provisional Application 60/531,406 filed Dec. 18, 2003 and to U.S. Provisional Application 60/554,342 filed Mar. 17, 2004 and to U.S. Provisional Application 60/615,614 filed Sep. 30, 2004. The text and drawings of each application set out above are hereby incorporated by reference into the present application as if fully set forth herein.
This invention relates to the use of 5 to 13 mer peptides and peptide derivatives for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders.
Additional background for therapeutic use of peptide fragments in the treatment of Alzheimer's disease and other amyloidoses can be found in U.S. patent application Ser. No. 09/938,275 filed Aug. 22, 2001, and in U.S. patent application Ser. No. 09/962,955 filed Sep. 24, 2001, the text and drawings of each of which are hereby incorporated by reference into the present application as if fully set forth herein.
Beta-Amyloid Protein as a Therapeutic Target for Alzheimer's Disease
Alzheimer's disease AD) is characterized by the deposition and accumulation of a 39-43 amino acid peptide termed the beta-amyloid protein, Aβ or β/A4 Glenner and Wong, Biochem. Biophys. Res. Comm. 120:885-890. 1984; Masters et al, Proc. Nat. Acad. Sci. U.S.A. 82:4245-4249, 1985; Husby et al, Bull. WHO 71:105-108, 1993). Aβ is derived from larger precursor proteins termed beta amyloid precursor proteins or APPs) of which there are several alternatively spliced variants. The most abundant forms of the APPs include proteins consisting of 695, 751 and 770 amino acids Kitaguchi et al, Nature 331:530-532, 1988; Ponte et al, Nature 331:525-527, 1988; Tanzi et al, Nature 331:528-530, 1988). The small Aβ peptide is a major component that makes up the core of amyloid deposits called “plaques” in the brains of patients with AD. In addition, AD is characterized by the presence of numerous neurofibrillary “tangles”, consisting of paired helical filaments which abnormally accumulate in the neuronal cytoplasm Grundke-lqbal et al Proc. Natl. Acad. Sci. U.S.A. 83:4913-4917, 1986; Kosik et al, Proc. Natl. Acad. Sci. U.S.A. 83:4044-4048, 1986; Lee et al, Science 251:675-678, 1991). The other major type of lesion found in AD brain is the accumulation of amyloid in the walls of blood vessels, both within the brain parenchyma and meningeal vessels that lie outside the brain. The amyloid deposits localized to the walls of blood vessels are referred to as cerebrovascular amyloid or congophilic angiopathy Mandybur, J. Neuropath. Exp. Neurol. 45:79-90, 1986; Pardridge et al, J. Neurochem. 49:1394-1401, 1987). The pathological hallmarks of AD therefore are the presence of “plaques”, “tangles”, and cerebrovascular amyloid deposits.
For many years there has been an ongoing scientific debate as to the importance of “amyloid” in AD and whether the “plaques” and “tangles” characteristic of this disease, were a cause or merely the consequences of the disease. Recent studies indicate that amyloid is indeed a causative factor for AD and should not be regarded merely as a consequence. The Alzheimer's Aβ protein in cell culture has been shown to cause degeneration of nerve cells within a short time period Pike et al, Br. Res. 563:311-314, 1991; J. Neurochem. 64:253-265, 1995). Studies suggest that it is the fibrillar structure, characteristic of all amyloids, that is mainly responsible for the neurologic effects. Aβ has also been found to be neurologic in slice cultures of hippocampus Hadrian et al, Neurobiol. Aging 16:779-789, 1995) and induces nerve cell death in transgenic mice Games et al, Nature 373:523-527, 1995; Hsiao et al, Science 274:99-102, 1996). Injection of Aβ into rat brain also causes memory impairment and neuronal dysfunction Flood et al, Proc. Natl. Acad. Sci. U.S.A. 88:3363-3366, 1991; Br. Res. 663:271-276, 1994). Convincing evidence that Aβ amyloid is directly involved in the pathogenesis of AD comes from genetic studies. It was discovered that the increased production of Aβ could result from mutations in the gene encoding, its precursor, APP Van Broeckhoven et al, Science 248:1120-1122, 1990; Murrell et al, Science 254:97-99, 1991; Haass et al, Nature Med. 1:1291-1296, 1995). The identification of mutations in the APP gene which causes early onset familial AD is a strong argument that Aβ and amyloid are central to the pathogenetic process underlying this disease. Four reported disease-causing mutations have now been discovered which demonstrate the importance of Aβ in causing familial AD reviewed in Hardy, Nature Gen. 1:233-234, 1992). Lastly, recent studies suggest that a reduction in amyloid plaque load in APP transgenic mice lead to improvements in behavioral impairment and memory loss Chen et al, Nature 408:978-982, 2000; Janus et al, Nature 408:979-982, 2000; Morgan et al, Nature 408:982-985, 2000). This is the strongest argument to date that implicates that reduction of Aβ amyloid load in brain should be a central target for the development of new and effective treatments of AD and related disorders.
In addition, besides Alzheimer's disease, a number of other beta-amyloid protein diseases involve formation, deposition, accumulation and persistence of Aβ fibrils, including Down's syndrome, disorders involving congophilic angiopathy, such as but not limited to, hereditary cerebral hemorrhage of the Dutch type, inclusion body myositosis, dementia pugilistica, cerebral β-amyloid angiopathy, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration and mild cognitive impairment.
Modulators of APP Secretases as Therapeutic Targets for Alzheimer's Disease
Elucidating APP metabolism and its role in the formation of Aβ plaques in AD is becoming increasingly important as therapeutics for AD and other beta-amyloid protein diseases are sought. Intracellular trafficking and proteolytic processing of APP directly influences the amount and type of Aβ peptide and can thus have a profound impact on amyloid plaque load.
Processing of APP in vivo and in cultured cells occurs by two major pathways Haass and De Strooper, Science 2865441):916-9 1999) and; Selkoe, Physiol Rev. 81 2):741-66, 2001)). Cleavage of APP at the N-terminus of the Aβ region by β-secretase and at the C-terminus by γ-secretases represents the amyloidogenic pathway for processing of APP. β-secretase cleaves APP between residues Met595 and Asp596 codon numbering refers to the APP695 isoform), and yields Aβ peptide plus the β-C-terminal fragment βCTF or C99). Following β-secretase cleavage, a second cleavage by γ-secretase occurs at the C-terminus of Aβ peptide that releases Aβ from CTF. This cleavage occurs in the vicinity of residue 636 of the C-terminus. γ-secretase can cleave the C-terminal region at either Val636 or Ile638 to produce a shorter Aβ peptide Aβ1-40) or the longer Aβ peptide Aβ1-42). The predominant form of Aβ found in the cerebrospinal fluid and conditioned media of cultured cells is the shorter Aβ40 peptide. Despite its lower abundance, Aβ42 is the peptide that is initially deposited within the extracellular plaques of AD patients. In addition, Aβ42 is shown to aggregate at a much lower concentration than the Aβ40 form. Alternatively, APP can also be processed via the non-amyloidogenic pathway whereby α-secretase cleaves within the Aβ domain between Lys611 and Leu612, and produces a large soluble APP domain sAPPα) and the αC-terminal fragment αCTF or C83). The latter can then be cleaved by γ-secretase at residue 636 or 638 to release a P3 peptide and the APP intracellular domain AICD). The α-cleavage pathway is the major pathway used to process APP in vivo; it does not yield Aβ peptide Selkoe, Physiol Rev. 812):741-66, 2001). The characterization of APP cleavage and the related secretases has provided significant advancement in therapeutic strategies that may lead to limiting the deposition of Aβ peptide in the brain and eliminate or delay the associated pathological effects in AD.
Alzheimer's Disease and the Aging Population
Alzheimer's disease is a leading cause of dementia in the elderly, affecting 5-10% of the population over the age of 65 years Jorm, A Guide to Understanding of Alzheimer's Disease and Related Disorders, New York University Press, New York, 1987). In AD, the parts of the brain essential for cognitive processes such as memory, attention, language, and reasoning degenerate. In some inherited forms of AD, onset is in middle age, but more commonly, symptoms appear from the mid-60's onward. AD today affects 4-5 million Americans, with slightly more than half of these people receiving care in many different health care institutions. The prevalence of AD and other dementias doubles every 5 years beyond the age of 65, and recent studies indicate that nearly 50% of all people age 85 and older have symptoms of AD NIH Progress Report on AD, National Institute on Aging, 2000). Thirty-three million people of the total population of the United States are age 65 and older, and this will climb to 51 million people by the year 2025 NIH Progress Report on AD, National Institute on Aging, 2000). The annual economic toll of AD in the United States in terms of health care expenses and lost wages of both patients and their caregivers is estimated at $80 to $100 billion NIH Progress Report on AD, National Institute on Aging, 2000).
Small peptides are disclosed which demonstrate great efficacy in inhibiting and/or disrupting amyloid fibrils. Also disclosed is the use of the same peptides for imaging the location of Aβ in the body for the purpose of diagnosis of Alzheimer's disease and other beta-amyloid protein Aβ) fibrillogenesis disorders, as well as the use of the same peptides for detecting Aβ in biological samples for the purpose of diagnosis of Alzheimer's disease and other beta-amyloid protein Aβ) fibrillogenesis disorders. “Fibrillogenesis” as used herein means the clinical or pathological binding of beta-amyloid to itself to form fibrils, and sometimes beta sheets, as known to those skilled in the art.
This disclosure pertains to compounds and pharmaceutical compositions thereof, that can bind to beta-amyloid protein Aβ) and modulate or moderate the aggregation and/or fibrillogenisis of Aβ, for the treatment and diagnosis of Aβ diseases such as Alzheimer's disease and other disorders that involve the accumulation and persistence of Aβ. These Aβ diseases include, but are not limited to, the amyloid associated with Alzheimer's disease and Down's syndrome, and various forms of cerebral amyloidosis, such as will be familiar to those knowledgeable in the art.
The disclosure relates to the novel and surprising discovery that certain peptides are binders and disruptors of Aβ amyloid fibrils, and are therefore useful for the therapeutic intervention of Alzheimer's disease and related Aβ disorders. Selected peptides are binders of Alzheimer's disease Aβ amyloid, and are therefore useful for the imaging and diagnosis of Alzheimer's disease and related Aβ disorders. Methods are disclosed for treating Alzheimer's disease and other Aβ disorders, comprising administering to a subject or patient a therapeutically effective dose of a selected 6-9mer peptide.
In one embodiment, in which preferably all amino acids indicated are D-amino acids, except where otherwise indicated such as by designating L-form peptides with “LP” number codes, or prefixing selected amino acid codes with “L-”), pharmaceutical compositions preferably contain at least one I peptide selected from the group of peptides comprising Ala-Gly-Gln-Trp-His-Arg-Val DP-026), Gly-Gln-Trp-His-Arg-Val-Ser DP-027), Gln-Trp-His-Arg-Val-Ser-Val DP-028), Trp-His-Arg-Val-Ser-Val-Arg DP-029), His-Arg-Val-Ser-Val-Arg-Trp DP-030), Arg-Val-Ser-Val-Arg-Trp-Gly DP-031), Asp-Gly-Arg-Trp-His-Arg-Val DP-032), Gly-Arg-Trp-His-Arg-Val-Ala DP-033), Arg-Trp-His-Arg-Val-Ala-Val DP-034), Trp-His-Arg-Val-Ala-Val-Ile DP-035), His-Arg-Val-Ala-Val-Ile-Met DP-036), Arg-Val-Ala-Val-Ile-Met-Gly DP-037), Thr-Leu-Phe-Leu-Ala-His-Gly DP-038), Leu-Phe-Leu-Ala-His-Gly-Arg DP-039), Phe-Leu-Ala-His-Gly-Arg-Leu DP-040), Leu-Ala-His-Gly-Arg-Leu-Val DP-041), Ala-His-Gly-Arg-Leu-Val-Phe DP-042), His-Gly-Arg-Leu-Val-Phe-Met DP-043), Gly-Leu-Ala-Phe-Val-Leu-Arg DP-044), Leu-Ala-Phe-Val-Leu-Arg-Gly DP-045), Ala-Phe-Val-Leu-Arg-Gly-Lys DP-046), Phe-Val-Leu-Arg-Gly-Lys-Ser DP-047), Val-Leu-Arg-Gly-Lys-Ser-Leu DP-048), Leu-Arg-Gly-Lys-Ser-Leu-Tyr DP-049), Arg-Val-Ala-Val-Ille-Met-Pro-Arg-Val-Ala-Val-Ile-Met DP-050), Trp-His-Arg-Val-Ala-Val-Ile-Met DP-051), Arg-Val-Ala-Val-Ile-Met DP-052), His-Arg-Pro-Ala-Val-Ile-Met DP-053), His-Arg-Val-Pro-Val-Ile-Met DP-054), His-Arg-Val-Ala-Val-Pro-Met DP-055), Leu-Ala-Phe-Val-Leu-Arg DP-056), Leu-Pro-Phe-Val-Leu-Arg DP-057), Arg-Arg-Pro-Ala-Phe-Val-Leu-Arg DP-058), Thr-Arg-Ile-Ser-Leu-Gln-Val DP-059), Ser-Leu-Gln-Val-Gln-Leu-Arg DP-060), Gln-Val-Gln-Leu-Arg-Lys-Arg DP-061), Arg-Val-Ser-Val-Arg-Trp DP-062), Arg-Val-Ser-Val-Arg DP-063), His-Pro-Arg-Leu-Val-Phe-Met DP-064), Trp-His-Arg-Val-Ala-Val-Ile-Met-amide DP-065), Trp-His-Arg-Val-Ala-Val-Ile-amide DP-066), Arg-Val-Ala-Val-Ile-Met-amide DP-067), Arg-Val-Ala-Val-Ile-Met-Gly-amide DP-068), Leu-Ala-Phe-Val-Leu-Arg-amide DP-069), His-Gly-Arg-Leu-Val-Phe-Met-amide DP-070), Thr-Leu-Phe-Leu-Ala-Arg DP-071), Trp-His-Leu-Ala-Phe-Val-Leu-Arg DP-072), Acetyl-Leu-Ala-Phe-Val-Leu-Arg-amide DP-073), Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-074), Thr-Leu-Phe-Leu-Ala-Arg-amide DP-075), Acetyl-Thr-Leu-Phe-Leu-Ala-Arg-amide DP-076), Thr-Leu-Phe-Leu-Ala-Arg-Lys DP-077), Thr-Leu-Phe-Leu-Ala-Arg-Lys-amide DP-078), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-amide DP-079), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-080). The group also includes certain analogs, derivatives, enantiomers, or fragments of the disclosed sequences herein as further discussed herein, and all hereafter referred to for easy reference as Sequence Group A.
In certain preferred embodiments, a compound has the general formula, or structure: Y—X-aa)-Z wherein X-aa) is essentially a peptide selected from the group consisting of -Arg-Val-Ser-Val-Arg-Trp-, -Arg-Val-Ala-Val-Ile, -His-Gly-Arg-Leu-Val-Phe-, -Leu-Ala-Phe-Val-Leu-Arg-, or -Thr-Leu-Phe-Leu-Ala-Arg-; and wherein Y— is an amino terminal N-terminal) modifying group which can be another an amino acid, a N-acylated amino acid, a peptide, a N-acylated peptide, or hydrogen, or other known N-terminus modifying compounds, and wherein Z is carboxyl-terminal C-terminal) modifying group selected from the group consisting of hydrogen, an amino acid, a C-amidated amino acid, a peptide, a C-amidated peptide, or other known C-terminal modifying groups.
Examples of peptides from Sequence Group A that work in the Y—X-aa)-Z model, hereafter referred to as Sequence Group B, include, His-Arg-Val-Ser-Val-Arg-Trp DP-030) Arg-Val-Ser-Val-Arg-Trp-Gly DP-031), Trp-His-Arg-Val-Ala-Val-Ile DP-035), His-Arg-Val-Ala-Val-Ile-Met DP-036), Arg-Val-Ala-Val-Ile-Met-Gly DP-037), Ala-His-Gly-Arg-Leu-Val-Phe DP-042), His-Gly-Arg-Leu-Val-Phe-Met DP-043), Trp-His-Arg-Val-Ala-Val-Ile-Met DP-051), Leu-Ala-Phe-Val-Leu-Arg DP-056), Trp-His-Arg-Val-Ala-Val-Ile-amide DP-066), Arg-Val-Ala-Val-Ile-Met-Gly-amide DP-068), Leu-Ala-Phe-Val-Leu-Arg-amide DP-069), His-Gly-Arg-Leu-Val-Phe-Met-amide DP-070), Thr-Leu-Phe-Leu-Ala-Arg DP-071), Trp-His-Leu-Ala-Phe-Val-Leu-Arg DP-072), Acetyl-Leu-Ala-Phe-Val-Leu-Arg-amide DP-073), Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-074), Acetyl-Thr-Leu-Phe-Leu-Ala-Arg-amide DP-076), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-amide DP-079), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-080).
It is preferable to select a peptide Y—X-aa)-Z as defined above but containing X-aa) peptides selected from -Arg-Val-Ala-Val-Ile-, -Leu-Ala-Phe-Val-Leu-Arg-, Thr-Leu-Phe-Leu-Ala-Arg-. Examples of these preferred structures hereafter referred to as Sequence Group C include Trp-His-Arg-Val-Ala-Val-Ile DP-035), His-Arg-Val-Ala-Val-Ile-Met DP-036), Arg-Val-Ala-Val-Ile-Met-Gly DP-037), Trp-His-Arg-Val-Ala-Val-Ile-Met DP-051), Trp-His-Arg-Val-Ala-Val-Ile-amide DP-066), Arg-Val-Ala-Val-Ile-Met-Gly-amide DP-068), Leu-Ala-Phe-Val-Leu-Arg DP-056), Leu-Ala-Phe-Val-Leu-Arg-amide DP-069), Trp-His-Leu-Ala-Phe-Val-Leu-Arg DP-072), Acetyl-Leu-Ala-Phe-Val-Leu-Arg-amide DP-073), Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-074), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-amide DP-079), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-080), Thr-Leu-Phe-Leu-Ala-Arg DP-071), Acetyl-Thr-Leu-Phe-Leu-Ala-Arg-amide DP-076).
Preferred efficacious peptide fragments in this disclosure are -Arg-Val-Ser-Val-Arg-Trp-, -Arg-Val-Ala-Val-Ile-, -His-Gly-Arg-Leu-Val-Phe-, -Leu-Ala-Phe-Val-Leu-Arg-, and -Thr-Leu-Phe-Leu-Ala-Arg-. These preferred fragments may be therapeutically employed either alone, in combination with each other, as foundations for further synthesis, or as otherwise disclosed herein.
Also disclosed is the use of N-methylated analogs of Sequence Group A, B, or C, including the use of αN-methylation or L-amino acids preferably methylated amino acids) exclusively or partially during synthesis such that the resulting peptides will have purely αN-methylated amide bonds or partially αN-methylated or alternating αN-methylated and non-αN-methylated amide bonds. Preferred compounds are selected from Sequence Group A, B, or C with modified amide bonds such that at least one of the amide bonds in the peptide back-bone is N-methylated, preventing the peptide itself from beta-sheet formation.
Mimetic peptidomimetic) compounds are also disclosed as modeled from other peptides disclosed herein, including the peptides of Sequence Group A, B, or C. The term “mimetic” generally includes “isosteres”, such as modifications of the peptide backbones i.e. amide bond mimetics) with amide nitrogen, amide carbonyl, or complete replacement of the amide bond. The amide bond can advantageously be replaced by similar length bridges known to those skilled in the art, such as: —CH2S—, —CH═CH—, —CH2NH—, —CSNH2—, or COCH2.
Mimetics can be generated using software that can derive a virtual peptide model from several of the peptide structures disclosed herein. This can be done using the software derived from SLATE algorithm. See, Perkin, Mills and Dean, 1995 Journal of Computer Aided Molecular Design 96) p 479-490; Mills et al. 2001 Journal of Computer Aided Molecular Design 151) p 81-96; De Esch, I J, et al 2001 Journal of Med. Chem. 4411) p 1666-74; Mills Perkins and Dean 1997 Journal of Computer Aided Molecular Design 11 2) p 175-92). One example of the program derived from SLATE algorithm is Quasi by De Novo Pharmaceutical. This program superimposes several active but apparently dissimilar peptide molecules that are active to arrive at the most probable structures essential for activity with minimum energy constraint). This can be used to generate a mold or target binding site with predicted position of hydrogen binding atoms in three dimensional space. This can then be used to generate a non-peptide mimic of the original ligand peptides. These molecule generator softwares are now commercially available example Skelgen and Skelgen II).
A “mimetic” of a compound also refers to a compound in which chemical structures of the compound that are necessary for functional activity have been replaced with other chemical structures which mimic the conformation of the compound or peptides thereof. The term “mimetic” as used herein is also intended to include molecules which mimic the chemical structure of a L or D-peptidic structure, and retain the functional properties of a L- or D-peptidic structure. Other approaches to designing peptide analogs, derivatives and mimetics are also well known in the art. For example, see P. S. Farmer, in Drug Design, E. J. Ariens, ed., Academic Press, New York, 1980, v. 10, pp. 119-143; Ball and Alewood, J. Mol. Recognition. 3:55, 1990; Morgan and Gainor, Ann. Rep. Med. Chem. 24:243, 1989; and Freidinger, Trends Pharmacol. Sci. 10:270, 1989. See also Sawyer, “Peptidomimetic design and chemical approaches to peptide metabolism”, in M D Taylor and G L Amidon, eds., in Peptide-Based Drug Design: Controlling Transport and Metabolism, Ch. 17, 1995; Smith et al, J. Am. Chem. Soc. 117:11113-11123, 1995; Smith et al, J. Am. Chem. Soc. 116:9947-9962, 1994; and Hirschman et al, J. Am. Chem. Soc. 115:12550-12568, 1993.
The term “analogs” includes variants of the peptide molecule brought about by, for example, homologous substitution of one or more amino acid residues as will be appreciated by those skilled in the art, reversal of the sequence, or partial or complete replacement of component amino acids with compositionally identical enantiomers D-vs L-amino acids). Analogs also include “conservative amino acid substitutions” in which one amino acid is substituted with an amino acid having a similar side chain. Examples of similar side chain amino acids, are basic side chain amino acids e.g., lysine, arginine, histidine), acidic side chain amino acids e.g., aspartic acid, glutamic acid), non polar side chain amino acids e.g., glycine, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), uncharged polar side chain amino acids e.g., aspargine, glutamine, serine, threonine, tyrosine, cystine), branched side chain amino acids e.g., threonine, leucine, valine, isoleucine) and aromatic side chain amino acids e.g., tyrosine, phenylalanine, tryptophan, histidine). Analogs also include “homolougous amino acid substitutions” in which an amino acid is substituted with homologous amino acids, such as replacement of phenyalanine with tyrosine, pyridylalanine, or homophenylalanine, and replacement of leucine with valine, or vice versa.
The term “derivative” includes minor chemical changes familiar to those skilled in the art in which one or more reactive groups on Sequence Group A, B, or C peptides have been “peptide derivatized” such that there are peptides in which an amino acid side chain, peptide backbone, or amino- or carboxy-terminus has been derivatized as further discussed herein.
In any of the above structures or sequences, the nomenclature or symbolic representation of any or all of the individual amino acids are given by the standard 3-letter abbreviation for the amino acids preceded optionally by either D- or L-representing the 2 enantiomeric forms mirror images of each other) of individual amino acids making up the sequence. Acetyl- and -amide at the N- and C-terminal respectively are optionally included when present or indicated as preferred.
Also disclosed are compounds that include Sequence Group A, B, or C peptides, portions of Sequence Group A, B, or C peptides and their novel analogs and derivatives thereof, the administration of which comprises a method for treating Alzheimer's disease and other Aβ amyloidoses. A method is thus provided for treating Alzheimer's disease and other disorders involving the formation and persistence of Aβ, comprising the administration to the subject a therapeutically effective amount of a compound such that the subject is treated for disorder associated with Aβ amyloidosis. Preferably, the disorders are Alzheimer's disease, Down's syndrome and other Aβ amyloidoses. Typically, the pharmaceutical composition includes a therapeutically effective amount of a disclosed compound or pharmaceutically acceptable salts of a compound, with optional pharmaceutically acceptable carrier, diluent or excipient.
Also disclosed is the use of pills, tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixers, suspensions, emulsions, solutions, syrups, tea bags, aerosols as a solid or in a liquid medium), suppositories, sterile injectable solutions, and sterile packaged powders, which contain a disclosed compound to treat patients with Alzheimer's disease and other Aβ amyloidoses. Therefore, the use of a disclosed compound for therapy or for the manufacture of a medicament for the treatment of a disorder associated with Aβ amyloidoses is also contemplated.
Compositions and methods involving administering to a subject a therapeutic dose of a selected disclosed compound that inhibits Aβ amyloid deposition, or Aβ amyloidosis in disorders in which Aβ amyloid deposition occurs are provided. Disclosed compounds can be used therapeutically to treat amyloidosis or can be used prophylactically in a subject susceptible to Aβ amyloidosis. The methods are based, at least in part, on directly binding Aβ amyloid either in the brain or in peripheral circulation, inhibiting Aβ amyloid fibril formation, and/or causing dissolution of pre-formed Aβ amyloid fibrils. Peripheral sequestration of Aβ by Sequence Group A, B, or C compounds is believed to result in movement of Aβ from the brain to the peripheral circulation, thereby inhibiting brain Aβ amyloid fibril formation, and/or causing dissolution of pre-formed brain Aβ amyloid fibrils.
Methods for detecting the presence or absence of Aβ peptides in a biological sample are provided. These methods include contacting a biological sample with a selected compound, wherein the compound is labeled with a detectable substance, for example, with a radionucleotide, phosphorescent compound, fluorescent compound, fluorescent protein, paramagnetic compound, metal chelators, or enzyme, all of which are readily detectable in various assays and diagnostics know to those skilled in the art, and then detecting the detectable substance bound to Aβ peptides in the biological sample.
Methods for imaging the presence or absence of Aβ peptides in the body or biological tissues are provided. These methods include contacting Aβ peptides in the body with a compound, wherein the compound is labeled with detectable substance, for example, with a radionucleotide, phosphorescent compound, fluorescent compound, fluorescent protein, paramagnetic compound, metal chelator, or enzyme, and detecting the detectable substance bound to Aβ peptides in the body or biological tissues.
Use of anti-idiotypic antibodies to Sequence Group A, B, or C peptides, analogs, derivatives or fragments thereof, as potent binders of Aβ, and inhibitors of Aβ amyloid formation, deposition, accumulation and/or persistence in Alzheimer's disease and other Aβ amyloidosis is presented. The term “anti-idiotypic antibodies” refers to the antibodies A) raised against or that specifically recognize the Fab regions of other antibodies B), and the Fab regions of antibodies B, recognize one of the peptides in Sequence Group A, B, or C. The result is that the anti-idiotypic antibodies A to Sequence Group A, B, or C peptides have Fab regions mimicking a Sequence Group A, B, or C peptide, in terms of reactivity, amyloid binding and amyloid disrupting properties.
Use of antibodies recognizing compounds for in vivo labeling is presented; for example, with a radionucleotide, for radioimaging to be utilized for in vivo diagnosis, and/or for in vitro diagnosis.
An important Aβ amyloidosis to which the disclosed therapeutics is addressed is Alzheimer's disease. A preferred therapeutically effective amount of disclosed compound is a dosage in the range of from about 10 μg to about 50 mg/kg body weight/per day, and more preferably in the range of from about 100 μg to about 10 mg/kg body weight per day.
A pharmaceutical agent containing a selected disclosed compound may advantageously be given by injection or infusion or nasal drop or nasal spray or oral administration. In any of the above structures or sequences, the nomenclature or symbolic representation of any or all of the individual amino acids may be given by either the standard 3-letter abbreviation for the amino acid, or the standard single letter code for the amino acid, and sometimes both in appropriate cases.
In one embodiment, there is disclosed the use of a peptide comprising Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid either for the reduction of beta-amyloid protein Aβ) in vivo or for the treatment of beta-amyloid protein diseases such as Alzheimer's disease, Down's syndrome, congophilic angiopathy, hereditary cerebral hemorrhage of the Dutch type, inclusion body myositosis, dementia pugilistica, cerebral β-amyloid angiopathy, dementia associated with progressive supranuclear palsy, dementia associated with cortical basal degeneration and mild cognitive impairment. Additionally, the amino acids in the peptide can be N-methylated.
In another embodiment, there is disclosed the use of a pharmaceutical composition comprising the peptide Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for the treatment of beta-amyloid protein diseases wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, diluent or excipient.
In another embodiment, there is disclosed the use of a pharmaceutical composition comprising the peptide Leu-Ala-Phe-Val-Leu-Arg-Lys-amide having at least one D amino acid for modulating APP processing or for modulating activity of APP secretases wherein the secretase can be gamma or beta secretase. The pharmaceutical composition can be used in a dosage in the range of from about 10 μg to about 100 mg/kg body weight/day or from about 100 μg to about 50 mg/kg body weight/day and can be administered in a subcutaneous, interperitoneal, intramuscular, parenteral injectable form, or in infusible form or either orally or by nasal spray.
The following drawings are illustrative of embodiments of the invention and are not meant to limit the scope of the invention.
The peptides disclosed herein were produced in both the L- and D-amino acid forms. In addition, truncated peptides and peptide analogs were assembled for use as potential therapeutic peptides for the treatment of Aβ fibrillogenesis in Alzheimer's disease and related disorders. These peptides are preferably conventionally synthesized. For example, L- and D-peptides were synthesized on peptide synthesizers known to those skilled in the art, such as the Advanced ChemTech Model 396 multiple peptide synthesizer Louisville, Ky.), using an automated protocol established by the manufacturer for 0.025 mmole scale synthesis. Double couplings were performed on all cycles using 2-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate HBTU)/N,N-diisopropylethylamine DIEA)/HOBt/FMOC-AA in four-fold excess for 30 minutes, followed by DIC/HOBt/FMOC-AA in fourfold excess for 45 minutes.
The peptide was then de-protected and removed from the resin by treatment with TFA/water 95%/5%) for 3 hours and then precipitated with cold ether. The resulting solid was then pelleted by centrifugation 2400 rpm×10 min), and the ether was discarded. The solid was then be re-suspended in ether and re-centrifuged for the second time after which the ether was decanted for the second time. The solid was dissolved in 10% acetic acid and lyophilized to dryness ˜30 mg for 12 amino acid peptides; 18 mg for 7 amino acid peptides). The crude peptide was purified by preparative HPLC using instruments known to those skilled in the art, such as a HP 1100 series with diode array detector, with a Vydac C18 column 21×250 mm) using a 15%-40% acetonitrile gradient over 80 minutes at a flow rate of 5 ml/min). The primary fraction was then collected and re-analyzed for purity using analytical HPLC to ensure a single symmetrical peak at all wavelengths. The confirmation of structures and sequences was based on comparison of predicted molecular weights, to molecular weights obtained by ESI mass spectroscopy. These analyses were performed using instruments known to those skilled in the art, such as a Sciex API IIIE triple quadruple ion spray mass spectrometer or ESI Agilent MSD-SL. 12-13mer peptides were synthesized with the following sequences, preferably all employing D-amino acids, except where otherwise indicated:
Arg-Lys-Arg-Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr DP-001), Arg-Gln-Val-Phe-Gln-Val-Ala-Tyr-Ile-Ile-Ile-Lys-Ala DP-002), Tyr-Leu-Ser-Lys-Gly-Arg-Leu-Val-Phe-Ala-Leu-Gly DP-003), Thr-Leu-Phe-Leu-Ala-His-Gly-Arg-Leu-Val-Phe-Met DP-004), Ala-Gly-Gln-Trp-His-Arg-Val-Ser-Val-Arg-Trp-Gly DP-005), Asp-Gly-Arg-Trp-His-Arg-Val-Ala-Val-Ile-Met-Gly DP-006), His-Gln-Thr-Trp-Thr-Arg-Asn-Leu-Gln-Val-Thr-Leu DP-007), Ile-Ser-Asn-Val-Phe-Val-Gln-Arg-Leu-Ser-Leu-Ser DP-008), Arg-Gly-Leu-Val-Phe-His-Thr-Gly-Thr-Lys-Asn-Ser-Phe DP-009), Gly-Asn-Ser-Thr-Ile-Ser-Ile-Arg-Ala-Pro-Val-Tyr DP-010), Val-Arg-Trp-Gly-Met-Gln-Gln-Ile-Gln-Leu-Val-Val DP-011), Ala-Pro-Val-Asn-Val-Thr-Ala-Ser-Val-Gln-Ile-Gln DP-012), Thr-Arg-Ile-Ser-Leu-Gln-Val-Gln-Leu-Arg-Lys-Arg DP-013), Ala-Lys-Ile-Ile-Ile-Tyr-Ala-Val-Gln-Phe-Val-Gln-Arg DP-014), Gly-Leu-Ala-Phe-Val-Leu-Arg-Gly-Lys-Ser-Leu-Tyr DP-015), Met-Phe-Val-Leu-Arg-Gly-His-Ala-Leu-Phe-Leu-Thr DP-016), Gly-Trp-Arg-Val-Ser-Val-Arg-His-Trp-Gln-Gly-Ala DP-017), Gly-Met-Ile-Val-Ala-Val-Arg-His-Trp-Arg-Gly-Asp DP-018), L-Arg-L-Lys-L-Arg-L-Leu-L-Gln-L-Val-L-Gln-L-Leu-L-Ser-L-Ile-L-Arg-L-Thr DP-019), and Arg-Val-Ala-Val-Ile-Met-Pro-Arg-Val-Ala-Val-Ile-Met DP-050).
In addition 6-9mer peptides including, iAβ5 LP-025) and piAβ5 LP-081) were synthesized with the following sequences and/or modifications:
L-Leu-L-Pro-L-Phe-L-Phe-L-Asp LP-025), Ala-Gly-Gln-Trp-His-Arg-Val DP-026), Gly-Gln-Trp-His-Arg-Val-Ser DP-027), Gln-Trp-His-Arg-Val-Ser-Val DP-028), Trp-His-Arg-Val-Ser-Val-Arg DP-029), His-Arg-Val-Ser-Val-Arg-Trp DP-030), Arg-Val-Ser-Val-Arg-Trp-Gly DP-031), Asp-Gly-Arg-Trp-His-Arg-Val DP-032), Gly-Arg-Trp-His-Arg-Val-Ala DP-033), Arg-Trp-His-Arg-Val-Ala-Val DP-034), Trp-His-Arg-Val-Ala-Val-Ile DP-035), His-Arg-Val-Ala-Val-Ile-Met DP-036), Arg-Val-Ala-Val-Ile-Met-Gly DP-037), Thr-Leu-Phe-Leu-Ala-His-Gly DP-038), Leu-Phe-Leu-Ala-His-Gly-Arg DP-039), Phe-Leu-Ala-His-Gly-Arg-Leu DP-040), Leu-Ala-His-Gly-Arg-Leu-Val DP-041), Ala-His-Gly-Arg-Leu-Val-Phe DP-042), His-Gly-Arg-Leu-Val-Phe-Met DP-043), Gly-Leu-Ala-Phe-Val-Leu-Arg DP-044), Leu-Ala-Phe-Val-Leu-Arg-Gly DP-045), Ala-Phe-Val-Leu-Arg-Gly-Lys DP-046), Phe-Val-Leu-Arg-Gly-Lys-Ser DP-047), Val-Leu-Arg-Gly-Lys-Ser-Leu DP-048), Leu-Arg-Gly-Lys-Ser-Leu-Tyr DP-049), Trp-His-Arg-Val-Ala-Val-Ile-Met DP-051), Arg-Val-Ala-Val-Ile-Met DP-052), His-Arg-Pro-Ala-Val-Ile-Met DP-053), His-Arg-Val-Pro-Val-Ile-Met DP-054), His-Arg-Val-Ala-Val-Pro-Met DP-055), Leu-Ala-Phe-Val-Leu-Arg DP-056), Leu-Pro-Phe-Val-Leu-Arg DP-057), Arg-Arg-Pro-Ala-Phe-Val-Leu-Arg DP-058), Thr-Arg-Ile-Ser-Leu-Gln-Val DP-059), Ser-Leu-Gln-Val-Gln-Leu-Arg DP-060), Gln-Val-Gln-Leu-Arg-Lys-Arg DP-061), Arg-Val-Ser-Val-Arg-Trp DP-062), Arg-Val-Ser-Val-Arg DP-063), His-Pro-Arg-Leu-Val-Phe-Met DP-064), Trp-His-Arg-Val-Ala-Val-Ile-Met-amide DP-065), Trp-His-Arg-Val-Ala-Val-Ile-amide DP-066), Arg-Val-Ala-Val-Ile-Met-amide DP-067), Arg-Val-Ala-Val-Ile-Met-Gly-amide DP-068), Leu-Ala-Phe-Val-Leu-Arg-amide DP-069), His-Gly-Arg-Leu-Val-Phe-Met-amide DP-070), Thr-Leu-Phe-Leu-Ala-Arg DP-071), Trp-His-Leu-Ala-Phe-Val-Leu-Arg DP-072), Acetyl-Leu-Ala-Phe-Val-Leu-Arg-amide DP-073), Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-074), Thr-Leu-Phe-Leu-Ala-Arg-amide DP-075), Acetyl-Thr-Leu-Phe-Leu-Ala-Arg-amide DP-076), Thr-Leu-Phe-Leu-Ala-Arg-Lys DP-077), Thr-Leu-Phe-Leu-Ala-Arg-Lys-amide DP-078), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-amide DP-079), Trp-His-Leu-Ala-Phe-Val-Leu-Arg-Lys-amide DP-080), and Acetyl-L-Leu-L-Pro-L-Phe-L-Asp-L-amide LP-081). D-indicates D-amino acids and L-indicates L-amino acids.
Circular dichroism CD) spectra of Aβ42 in the presence or absence of synthetic peptides outlined in Example 1 were recorded at 25° C. on a JASCO-810 Spectropolarimeter using a 0.5 mm path length quartz cuvette, and over the range of 190-260 nm. The instrument was calibrated with an aqueous solution of +)camphorsulfonic acid. The instrument was then set to collect data at a bandwidth of 5 nm, response time of 32 seconds, data pitch of 0.5 nm, and a scan speed of 10 nm/min. Each CD spectrum was an average of 5 spectra, each taken from a separate replicate solution. The CD results were reported as Molar Residue Ellipticity MRE) of Aβ42, after subtraction of the background solvent spectrum and/or test peptide spectrum. For this study, fibrillar Aβ42 0.1 mg/ml) in TPBSF 10% TFE, 150 mM NaF, 50 mM HNaPO4, pH 7.4) was incubated for 3 days at 37° C. in the presence and absence of various 12-13mer peptides at an Aβ42:peptide wt/wt ratio of 1:2, before recording the CD spectra. The percent disruption of beta-sheet structure was determined by the calculating the percent loss of negative ellipticity at 218 nm compared to Aβ42 alone, after the corresponding blanks were subtracted.
Various peptides synthesized as outlined in Example 1 were tested for potential Aβ amyloid disrupting activity using a variety of in vitro assays. One such assay, Thioflavin T fluorometry, which measures the amount of amyloid fibrils LeVine III, Protein Sci. 2:404-410, 1993; Amyloid: Int. J. Exp. Clin. Invest. 2:1-6, 1995; Naiki and Nakakuki, Lab. Invest., 74:374-383, 1996; Castillo et al, J. Neurochem. 69:2452-2465, 1997) was used to identify synthetic peptides capable of disrupting Aβ42 amyloid fibrils. For these studies, 0.1 mg/ml of Aβ42 Bachem Inc) was incubated in microcentrifuge tubes at 37° C. for 3 days in triplicate), either alone, or in the presence of 0.2 mg/ml peptide at an Aβ:peptide weight ratio of 1:2) in TPBSF 10% TFE, 150 mM NaF, 50 mM HNaPO4, pH 7.4). Fifty μl aliquots were taken for analysis at day 3, and 200 ul aliquots of 125 μM Thioflavin T in 62 mM NaPO4 pH 6.0), were added to give a final Thioflavin T concentration of 100 μM and 62 mM of NaPO4. Fluorescence emission at 480 nm was measured on a microplate 96well-fluorometer Labsystem) at an excitation wavelength of 450 nm. For all determinations any fluorescence given off by peptides in the presence of the Thioflavin T reagent was always subtracted from all pertinent readings. Previous studies have indicated that increasing concentrations of fibrillar A42 gives a proportional increase in fluorescence in the presence of 100 μM Thioflavin T, ruling out the presence of any disproportionate inner filter effects at this Thioflavin T concentration Castillo et al J. Neurochem. 69:2452-2465, 1997).
Circular dichroism CD) spectropolarimetry is another in vitro technique used to determine a given peptide's effectiveness in disrupting the b-sheet secondary structure of Aβ-fibrils. CD spectra of Aβ42 in the presence or absence of synthetic peptides were recorded at 25° C. on a JASCO-810 Spectropolarimeter using a 0.5 mm path length quartz cuvette, and over the range of 190-260 nm. The instrument was calibrated with an aqueous solution of +)camphorsulfonic acid. The instrument was then set to collect data at a bandwidth of 5 nm, response time of 32 seconds, data pitch of 0.5 nm, and a scan speed of 10 nm/min. Each CD spectrum was an average of 5 spectra, each taken from a separate replicate solution. The CD results were reported as Molar Residue Ellipticity MRE) of Aβ42, after subtraction of the background solvent spectrum and/or test peptide spectrum. For this study, fibrillar Aβ42 0.1 mg/ml) in TPBSF 10% TFE, 150 mM NaF, 50 mM HNaPO4, pH 7.4) was incubated for 3 days at 37° C. in the presence and absence of various peptides at an Aβ42:peptide wt/wt ratio of 1:2, before recording the CD spectra. The percent disruption of beta-sheet structure was determined by the calculating the percent loss of negative ellipticity at 218 nm compared to Aβ42 alone after the corresponding blanks were subtracted.
Thioflavin T fluorometry, which measures the amount of amyloid fibrils LeVine III, Protein Sci. 2:404-410, 1993; Amyloid: Int. J. Exp. Clin. Invest. 2:1-6, 1995; Naiki and Nakakuki, Lab. Invest., 74:374-383, 1996; Castillo et al, J. Neurochem. 69:2452-2465, 1997) was also used to determine the effectiveness of 6-9mer peptides on disrupting Aβ42 amyloid fibrils. For these studies, 0.1 mg/ml of Aβ42 Bachem Inc) was incubated in microcentrifuge tubes at 37° C. for 3 days in triplicate), either alone, or in the presence of 0.2 mg/ml peptide at an Aβ:peptide weight ratio of 1:2) in TPBSF 10% TFE, 150 mM NaF, 50 mM HNaPO4, pH 7.4). Fifty μl aliquots were taken for analysis at day 3 and 200 ul aliquots of 125 μM Thioflavin T in 62 mM NaPO4 pH 6.0), were added giving a final Thioflavin T concentration of 100 μM and 62 mM of NaPO4. Fluorescence emission at 480 nm was measured on a microplate 96well fluorometer Labsystem) at an excitation wavelength of 450 nm. For all determinations any fluorescence given off by peptides in the presence of the Thioflavin T reagent was always subtracted from all pertinent readings. Previous studies have indicated that increasing concentrations of fibrillar Aβ42 gives a proportional increase in fluorescence in the presence of 100 μM Thioflavin T, ruling out the presence of any disproportionate inner filter effects at this Thioflavin T concentration Castillo et al J. Neurochem. 69:2452-2465, 1997).
The ability of various peptides to bind to substrate bound Aβ42 was determined by a solid phase binding assay along with a determination of unbound peptide fractions using high pressure liquid chromatography attached to a mass selective detector HPLC/MSD; Agilent 1100 HPLC system). The peptides were resolved in HPLC using a Synergi-Max RP 2×0.4 cm; 2 um) column from phenomenex with a flow rate of 1 ml/min and a gradient of 0-60% acetonitrile in water, containing 1% formic acid over 5.5 minutes. The peptides were detected as they come out from the column using MSD SL Agilent). The MSD had the following settings: Positive ion monitoring in scan mode from 200-1200 Da; fragmentor voltage, 150; drying gas flow, 13 L/min N2; nebuliser pressure, 45 psi; drying gas temperature, 350° C.; and capillary voltage, 3500 volts.
The solid phase binding assay was performed as follows: 10 ug aliquots of Aβ42 were bound to PVDF membrane at the bottom of a 96-well microplate available from Millipore), according to the manufacturer's instructions. The plate was allowed to dry and aliquots of 150 ul of 0.1 mg/ml of 6-9mer peptides were applied in each well. Each 6-9mer peptide was applied in triplicate in the Aβ42-containing wells test wells), and in triplicate in the non-Ab42 containing wells blank wells). The plates containing 16 different 6-9mer peptides was incubated at 37° C. for 2 hrs. The unbound peptide in each well was then transferred to HPLC/MSD vials for analysis with the settings outlined above. The peptides recovered from wells without Aβ42 were taken as the total peptides, whereas the peptides recovered from wells with Aβ42, were taken as the total-bound peptides. The percentages of various peptides bound after 2 hrs of incubation were then plotted
Circular dichroism CD) spectropolarimetry is another in vitro technique used to determine a given peptide's effectiveness in disrupting the b-sheet secondary structure of Aβ-fibrils. CD spectra of Aβ42 in the presence or absence of synthetic 6-9mer peptides were recorded at 25° C. on a JASCO-810 Spectropolarimeter using a 0.5 mm path length quartz cuvette, and over the range of 190-260 nm. The instrument was calibrated with an aqueous solution of +)camphorsulfonic acid. The instrument was then set to collect data at a bandwidth of 5 nm, response time of 32 seconds, data pitch of 0.5 nm, and a scan speed of 10 nm/min. Each CD spectrum was an average of 5 spectra, each taken from a separate replicate solution. The CD results were reported as Molar Residue Ellipticity MRE) of Aβ42, after subtraction of the background solvent spectrum and/or test peptide spectrum. For this study, fibrillar Aβ42 0.1 mg/ml) in TPBSF 10% TFE, 150 mM NaF, 50 mM HNaPO4, pH 7.4) was incubated for 3 days at 37° C. in the presence and absence of various 6-9mer peptides at an Aβ42:peptide wt/wt ratio of 1:2, before recording the CD spectra.
The CD spectra of Aβ42 alone, Aβ42 plus 6-9mer peptide, and 6-9mer peptide alone, are presented in
Circular dichroism CD) spectropolarimetry is another in vitro technique used to determine a given peptide's effectiveness in disrupting the b-sheet secondary structure of Aβ-fibrils. CD spectra of Aβ42 in the presence or absence of synthetic 6-9mer peptides were recorded at 25° C. on a JASCO-810 Spectropolarimeter using a 0.5 mm path length quartz cuvette, and over the range of 190-260 nm. The instrument was calibrated with an aqueous solution of +)camphorsulfonic acid. The instrument was then set to collect data at a bandwidth of 5 nm, response time of 32 seconds, data pitch of 0.5 nm, and a scan speed of 10 nm/min. Each CD spectrum was an average of 5 spectra, each taken from a separate replicate solution. The CD results were reported as Molar Residue Ellipticity MRE) of Aβ42, after subtraction of the background solvent spectrum and/or test peptide spectrum. For this study, fibrillar Aβ42 0.1 mg/ml) in TPBSF 10% TFE, 150 mM NaF, 50 mM HNaPO4, pH 7.4) was incubated for 3 days at 37° C. in the presence and absence of various peptides at Aβ42:peptide wt/wt ratios of 1:0.1, 1:1, 1:2, and 1:10 before recording the CD spectra.
The CD spectra of Aβ42 alone, Aβ42 plus 6-9mer peptide, and peptide alone were presented in
A desirable characteristic of any potential therapeutic or drug candidate is the ability to resist degradation by enzymes in the blood, to have enough time reach its target. One of the in vitro assays used to determine the stability of peptides in Sequence Group A, B, or C is by incubating these peptides in human serum, and determining the level of the intact peptides and possible degradation) at various time points. Fifty ul aliquots of various peptides were added to 700 ul of human serum in triplicate samples). One hundred ul aliquots were then taken at 0, 2, 4, 6, 24, and 32 hrs, followed immediately with the addition of 200 ul of ethanol or 20 ul of trifluoroacetic acid or 300 ul methanol) and centrifuged at 14,000×g Eppendorf) for 10 minutes. The level of intact peptides in the supernatant was then determined using LC/MS Agilent HPLC/MS SL 1100 Series). MS monitored each peptide as it came out of the HPLC using SIM mode positive ion monitoring at masses corresponding to single, double and triple charge peptide ions. The peak in the resulting ion chromatograms were integrated to obtain total ion abundance in each sample. The average of triplicate determinations of total ion abundance for each serum incubation time-point was then plotted as a function of serum incubation time. Most of the peptide degrading enzymes in the body recognizes natural peptides made up of all L-amino acids. As the peptides consist of D-amino acids, their degradation in biological fluids will likely be retarded, as demonstrated in this Example and the following figures.
Further data are illustrated as follows:
1) cDNA Constructs, Cell Cultures and Stable Transfected Cell Lines
Mammalian expression constructs, pCA-APP695 and pcDNA3.1-APP695-myc, have been described by Fukuchi et al. J. Neurochem. 58: 1863-1873 1992) and Yang et al. J. Biol. Chem. 2817):4207-4214 2006), respectively. pCA-APP695 contains the cDNA sequence coding for the human full-length APP695, and is driven by a chicken actin promoter. pcDNA3.1-APP695-myc was generated by subcloning of an APP695 cDNA fragment from pCA-APP695 into the BamHI and EcoRI sites of the pcDNA3.1-myc/His vector Invitrogen), which is driven by a cytomegalovirus immediate-early promoter.
Two cell lines stably transfected with pCA-APP695 and pcDNA3.1-APP695-myc were generated to assess APP processing and Aβ generation in cell culture. Human Embryonic Kidney HEK) 293 cells ATCC #CRL-1573), and human brain neuroblastoma cells, SK-N-SH ATCC #HTB-11), were employed to generate the APP stable cell lines. Cells were routinely cultured in a regular growth media RGM) that contained Dulbecco's Modified Eagle Medium DMEM) Invitrogen) supplemented with 10% fetal bovine serum at 37° C. in a cell culture incubator supplemented with 5% CO2. HEK293 and SK-N-SH cells were grown to 70-80% confluence in 35 mm dishes, and transfected with 3 μg of pCA-APP695, and pcDNA3.1-APP695-myc, respectively. Transfection was mediated by polyethylenimines Polysciences, Inc.) as described by Hu et al. J. Biol. Chem. 28013):12548-12558 2005). Twenty-four hours after transfection, cells were plated at low density 400-2000 cells/plate), and grown in RGM containing 0.6-0.8 mg/ml G418 Invitrogen) to select stable colonies. After two weeks, stable colonies were picked, and sub-cultured. Stable expression of APP was confirmed by Western analysis of conditioned media for secreted APP using monoclonal antibody 6E10 Covance #SIG-39320), and of cell lysates for intracellular APP using an anti-APP C-terminal polyclonal antibody Sigma # A8717). The stable cell lines were maintained by periodic selection with G418-containing RGM. HEK293 cells stably transfected with pCA-APP695 are referred as HEK293-APP cells, while SK-N-SH cells stably transfected with pcDNA3.1-APP695-myc are referred as SKNSH-APP cells.
2) Treatment of Cultured Cells with 6-9 mer Peptides
Twenty-millimolar stock solutions of peptides DP-068 and DP-074 were prepared in PBS, aliquoted and stored at −80° C. before use. On the day before treatment, HEK293-APP and SKNSH-APP cells were plated in 6-well culture plates with low IgG growth media [DMEM+10% of low IgG fetal bovine serum Invitrogen #16250)]. The plating density allows cells to reach 80-95% of confluence on the next day. Upon treatment, cell culture media were replaced with 1.6 ml per well of low IgG growth media containing freshly-diluted peptides. Cells were incubated at 37° C. in a cell culture incubator for 20 hours. After incubation, conditioned media were collected, and centrifuged at 8000×g for 10 min at 4° C. to remove cell debris. Supernatants were saved and stored at −80° C. for analyses of secreted APPsAPPα) secreted APPβsAPPβ), and secreted Aβ peptides. Cell lysates were collected for determining intracellular levels of APP, CTFs and β-actin. Briefly, the cell monolayer was washed once with PBS, and directly lysed in 200 μl of 2× Laemmli sample buffer 75 mM Tris-HCl, pH 8.4, 4% SDS, 20% glycerol, 50 mM DTT, 0.004% bromphenol blue) on ice for 15 min. Lysates were collected, boiled at 100° C. for 10 min without centrifugation, and stored at −80° C. for Western analysis.
3) Immunoprecipitation of Aβ Peptides in Conditioned Media
The immunoprecipitation methodology was employed to enrich secreted Aβ peptides from conditioned media. In the assay, all centrifugation steps were conducted at 5,000 rpm in a bench-top centrifuge for 1 min at room temperature unless otherwise indicated. Twenty microliters of 50% protein-A/G agarose slurry PIERCE, #53135) per sample was aliquoted, and washed twice with cold PBS containing 0.01% Triton X-100 PBS-T) by mixing and spinning to remove the residues from the bead storage buffer. The beads were then resuspended in 0.8 ml of cold PBS-T containing 1.2 μg of monoclonal antibody mAb) 4G8 Covance #SIG-39220) that specifically recognizes amino acids 17-24 of the Aβ region, and incubated on an orbital rotator for 2 h at 4° C. to allow the mAb to bind to the protein-A/G. The mAb-bound beads were then centrifuged and washed twice with 1 ml of cold PBS-T to remove unbound mAb 4G8. Equal amounts of conditioned media 0.5-0.9 ml per sample) collected from peptide-treated cell cultures were added into the 4G8-containing tubes, and incubated at 4° C. on an orbital rotator overnight. The beads were then centrifuged, and washed once with 1 ml of cold PBS-T, and once with 1 ml of cold PBS by mixing and spinning. Bound Aβ peptides were eluted with 20 μl of 2× Laemmli sample buffer eliminating dithiothreitol to minimize the co-elution of IgG), followed by 4-min boiling and 2-min centrifugation at 8000 rpm. The supernatant was carefully collected in a fresh tube that contained 1/20 volume of 1M dithiothreitol, and stored at −30° C. for Bicine/Tris/Urea/SDS polyacrylamide gel electrophoresis PAGE).
4) Electrophoresis of Aβ Peptides
Secreted Aβ peptides were analyzed by a Bicine/Tris/Urea/SDS PAGE system described by Klafki et al., Analytical Biochem. 237:24 1996). Bicine/Tris/Urea/SDS/polyacrylamide mini gels 6 cm×9 cm×0.75 mm) were prepared the day before electrophoresis, and stored at 4° C. The gel system consists of a separating gel [10% of acrylamide/bis19:1; Bio-Rad #161-0144), 8M of urea, and 0.1% SDS prepared in separating buffer 0.4 M Tris; 0.1 M H2SO4)], a stacking gel [6% of acrylamide/bis19:1) and 0.1% SDS prepared in a stacking buffer 0.4 M Bistris; 0.1 M H2SO4)] and a comb gel [9% of acrylamide/bis19:1) and 0.1% SDS prepared in a comb gel buffer 0.36 M bistris; 0.16 M bicine)]. Immunoprecipitation elutes 8-10 μl per sample) were resolved in gels at 200 volts constant) for about one hour. The gel running buffers consist of a cathodic buffer 0.2M bicine; 0.1 M NaOH; 0.25% SDS) and an anodic buffer 0.2 M Tris; 0.05 M H2SO4). Peptide bands in gels were transferred onto Immobilon-PSQ membrane Millipore) using a Trans-Blot Semi-Dry system Bio-Rad) at 0.04 A constant) per mini-gel for 50 min. The transfer buffers Klafki et al. 1996) were buffer A 0.3 M Tris; 30% methanol), buffer B 25 mM Tris; 30% methanol), and buffer C 25 mM Tris, pH 9.4; 0.025% SDS). The transfer sandwich was set up from bottom to top as an extra-thick filter paper Bio-Rad) soaked in buffer A, an extra-thick filter paper soaked in buffer B, two layers of Immobilon-PSQ membranes the bottom layer was used to block peptides going through, and discarded after transfer) soaked in buffer B, the gel briefly soaked in buffer C for 1 min, and an extra-thick filter paper soaked in buffer C. After transfer, the membrane next to the gel was boiled in PBS for 3 min using a microwave oven before blocking with 5% milk in PBS containing 0.05% Tween-20.
5) Western Blotting
Cellular APP and CTFs in lysates were separated in 16.5% Tris/Tricine Criterion peptide gels Bio-Rad), whereas sAPPα and sAPPβ in conditioned media were separated in 4-12% Bis/Tris Criterion XT gels Bio-Rad), with buffer systems recommended by the manufacturer. After electrophoresis, protein bands were transferred onto Immobilon-PSQ membranes using Bio-Rad Criterion™ Blotters, and a transfer buffer system Bio-Rad). The transfer was conducted at 0.4 A constant) for 90-120 min at 4° C. All transferred membranes were blocked with 5% milk in PBS+0.05% Tween-20 for 30-60 min at room temperature, and incubated with primary antibodies for overnight at 4° C., and with HRP-conjugated secondary antibody Vector) at 1:4000 at room temperature for 2 h. Aβ peptides were detected using mAb 6E10 Covance; 1:3000), intracellular CTFs with a rabbit polyclonal antibody specifically recognizing the C-terminus of APP695 amino acids 676-695) Sigma; 1:50,000), sAPPα with mAb 6E10 Covance; 1:20,000), sAPPβ with a polyclonal antibody specific for secreted APPβ Covance; 1:500), and β-actin with mAb C4 Sigma; 1:200,000). Protein bands were visualized with an ECL system GE Healthcare) by exposing to autoradiography films. For re-probing membranes with a different antibody, membranes were stripped and reprobed with the next primary antibody. Quantitation of relative intensities of protein bands on autoradiographic films was performed by image quantification with the Scion Image software http://www.scioncorp.com).
6) ELISA
To evaluate Aβ levels, conditioned media from cells were measured with commercial ELISA kits The Genetics Company, Zurich, Switzerland) according to the manufacturer's instructions. For Aβ40, samples were diluted 1:2 with kit sample diluent buffer. For Aβ42, samples were applied to ELISA plates without dilution. Standards were prepared in low IgG media in the same dilution as the samples. Media or standards containing known amounts of Aβ were applied to micro-titre plates coated with monoclonal antibodies specific to the C-terminus of Aβ40 or Aβ42 and incubated overnight. After a wash step, captured Aβ was bound to a monoclonal biotin-conjugated antibody recognizing the N-terminus of Aβ. The biotinylated-Aβ complex was then bound to streptavidin-HRP and detected in an enzymatic calorimetric reaction. Samples were quantified by comparing the optical density 450 nm) of the standards to that of the unknowns.
7) Peptide DP-068 Modulates α, β, and γ Cleavage of APP and Reduces Aβ Peptide Generation in HEK293-APP Cells
and sAPP
were found in cells treated with peptide DP-068, when compared to PBS vehicle control. The reductions were dose-dependent. The reduction became evident at 80 μM treatment for sAPPα reduced by 11%), and at 200 μM for sAPPβ by 75%). At 400 μM and 800 μM treatments, sAPPα levels were reduced by 89% and 99%, respectively, while sAPPβ levels were non-detectable. The results indicate that peptide DP-068 is a potent agent that can modulate both α and β cleavage of APP.
8) Peptide DP-068 Modulates α, β, and γ Cleavage of APP and Reduces Aβ Generation in SKNSH-APP Cells
and sAPP
were found in cells treated with peptide DP-068, when compared to PBS vehicle control. The reductions were dose-dependent. Reduced levels of sAPP
down by 7-99%) and sAPPβ down by 17-100%) were observed in cells treated with 80-800 μM DP-068. The results confirm that peptide DP-068 can modulate α and β cleavage of APP in both HEK293-APP and SKNSH cell lines.
9) Peptide DP-074 Selectively Modulates β and γ Cleavage of APP and Reduces Aβ Generation in HEK293-APP Cells.
10) Peptide DP-074 Selectively Modulates β and γ Cleavage of APP and Reduces Aβ Generation in SKNSH-APP Cells.
)}. These results indicate that peptide DP-074 can selectively modulate α cleavage of APP without effect on a cleavage even at the highest dose tested.
Taken together, these results indicate that the 6-9 mer peptides modulate APP processing and reduce Aβ generation in cell culture. Our conclusions are based on endpoint measurements of direct APP cleavage products, including sAPPα, sAPPβ, CTFs, and Aβ peptides in two cell lines stably expressing the human wild type APP as measured by Western analysis, immunoprecipitation, and ELISA. DP-068 acts as a modulator that reduces the products of APP cleaved by all major secretases, including α, β and {tilde over (γ)} cleavage. This modulation also leads to reduced generation of Aβ peptides in conditioned media. In contrast, peptide DP-074 acts as a selective modulator that mainly reduces the products of the β and {tilde over (γ)} cleavage of APP, the two events that are essential for generating pathological A species in Alzheimer disease. More importantly, peptide DP-074 exerts no affect on a cleavage of APP, leaving the physiological pathway intact Postina, Curr Alzheimer Res. 52):179-86 2008)).
Other secretase modulators, specifically those which modulate gamma secretase GSM) have been reported to interact with residues 28-36 of the Aβ region of APP Kukar et al., Nature 4537197):925-9 2008). This is also a likely mechanism of action for peptides DP-068 and DP-074 which alter Aβ generation, disrupt Aβ aggregation and, consequently may reduce plaque formation and deposition in Alzheimer disease.
Further Aspects and Utilizations
One therapeutic application is to use peptides of Sequence Group A, B, or C as binders or sequesters of Aβ, inhibitors of Aβ amyloid fibril formation, inhibitors of Aβ amyloid fibril deposition, inhibitors of Aβ amyloid fibril accumulation and/or persistence, in Alzheimer's disease, Down's syndrome and other amyloid disorders involving Aβ fibrillogenesis.
“Peptide” refers to two or more amino acids linked together by peptide bonds as known to those skilled in the art. Preferred peptides are those disclosed herein, but may also advantageously include peptides which have at least a 70%, and more preferably an 80-90% identity to a disclosed peptide. “% Identity” as used herein for peptides means the same amino acids in the same place. Thus, two 10 amino acid peptides are 90% identical if juxtaposition to each other showed that the placement and identity of each amino acid is identical, except for one amino acid. If a ten amino acid peptide is juxtaposed to another ten amino acid peptide and the placement and identity of amino acids is identical, except for two amino acids, then the two 10 amino acid peptides have an 80% identity with each other.
Disclosed peptides are produced by chemical synthetic procedures. Chemical peptide synthesis is a rapidly evolving area in the art, and methods of solid phase peptide synthesis are well-described in the following references, hereby entirely incorporated by reference Merrifield, J. Amer. Chem. Soc. 85:2149-2154, 1963; Merrifield, Science 232:341-347, 1986; Fields, Int. J. Polypeptide Prot. Res. 35, 161, 1990). Disclosed peptides may also be utilized as research reagents and materials for discovery of treatments and diagnostics for human diseases.
The route of administration includes oral, intravenous, intra-peritoneal, intra-muscular, subcutaneous, intra-articular, intra-nasal, intra-thecal, intra-dermal, transdermal or by inhalation. An effective dose of each of the peptides disclosed herein as potential therapeutics for use in treating Aβ amyloidosis in Alzheimer's disease and other disorders is from about 1 μg to 500 mg/kg body weight, per single administration, which may readily be determined by one skilled in the art. The dosage depends upon the age, sex, health, and weight of the recipient, kind of concurrent therapy, if any, and frequency of treatment. Other effective dosage range upper limits are 100 mg/kg body weight, 50 mg/kg body weight, 25 mg/kg body weight, and 10 mg/kg body weight.
As used herein polypeptides may consist of -L amino acids, -D amino acids or a mixture of both forms. Amino acids in nature usually consist of -L amino acids. However, substitution with -D amino acids generally demonstrates enhanced bioavailability due to less degradation in biological fluids such as plasma), and enhanced penetration across the blood-brain-barrier. Polypeptides having an identical amino acid sequence to that found within a disclosed peptide, but in which all or part of the L-amino acids have been substituted with D-amino acids, is a part of the disclosed development of therapeutics to treat Alzheimer's disease and other Aβ amyloidoses.
As used herein “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. In one embodiment, the carrier is suitable for parenteral administration. Preferably, the carrier is suitable for administration into the central nervous system e.g. intraspinally or intracerebrally). Alternatively, the carrier can be suitable for intravenous, intraperitoneal or intramuscular administration. In another embodiment, the carrier is suitable for oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is compatible with the active compound, use thereof in the pharmaceutical compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
As used here in “Aβ amyloidoses” refers to amyloid diseases which involve the formation, deposition, accumulation and/or persistence of Aβ i.e. beta-amyloid protein), including but not limited to Aβ containing 39-43 amino acids in length, but more preferably, Aβ 1-40, or Aβ 1-42, and mixtures or fragments thereof.
“Aβ amyloidoses” and “Aβ fibrillogenesis diseases” include, but are not limited to Alzheimer's disease, Down's syndrome, forms of familial amyloidosis, cerebrovascular amyloidosis and cerebral hemorrhage, cystatin C amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis Dutch type), hereditary cerebral hemorrhage with amyloidosis Icelandic type), and inclusion body myositis.
Therapeutic Applications
In preferred embodiments, Sequence Group A, B, and C peptides, fragments, analogs, and derivatives thereof are used as amyloid inhibitory therapeutic agents. The Sequence Group A, B, and C peptides, fragments, analogs and derivatives thereof can be synthesized utilizing standard techniques i.e. using an automated synthesizer). In a preferred embodiment, specific Sequence Group A, B, or C peptides, fragments, analogs or derivatives thereof may be used to bind or sequester Aβ amyloid, inhibit Aβ amyloid formation, deposition, accumulation, and/or persistence in a given patient. Likewise, in another preferred embodiment anti-idiotypic antibodies made against Sequence Group A, B, or C peptides, fragments, analogs or derivatives thereof as described above) may be given to a human patient as potential Aβ binding or sequestering antibodies, that may disrupt or inhibit Aβ amyloid formation, deposition, accumulation and/or persistence in the given patient.
A formulation for use in the treatment of Aβ amyloidoses comprises a pharmaceutically effective amount of a peptide in Sequence Group A, B, or C, fragment, analog or derivative thereof, anti-idiotypic antibody, or anti-idiotypic antibody fragment which includes a pharmaceutically acceptable carrier. The formulations may additionally include other antibodies or conjugates. For parenteral administration, preferred formulations include sterile aqueous or non-aqueous solutions, suspensions, and emulsions, which may contain axillary agents or excipients that are known in the art. The anti-idiotypic antibody formulations can be administered using conventional modes of administration including, but not limited to, topical, intravenous, intra-arterial, intraperitoneal, oral, intralymphatic, intramuscular or intralumbar. Intravenous administration is preferred. Pharmaceutical formulations such as tablets, pills, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixers, suspensions, emulsions, solutions, syrups, tea bags, aerosols as a solid or in a liquid medium), suppositories, sterile injectable solutions, sterile packaged powders, can be prepared according to routine methods and are known in the art. The administration of such a composition may be by oral or various parenteral routes such as subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, anal or buccal routes. Parenteral administration can be by bolus injection or by gradual perfusion over time. Preferred modes of administration of the formulations of Sequence Group A, B, or C, fragments, analogs or derivatives thereof is by oral administration, intravenous, or intranasal application.
Compounds of Sequence Group A, B, or C, fragments, analogs and derivatives thereof, may be administered in the form of a pharmaceutical formulation by any means that achieve their intended purpose, for example, to treat pathologies, such as Alzheimer's disease and other Aβ amyloid diseases, or other related pathologies. The therapeutic formulations can be a variety of dosage forms, with the preferred form depending upon the mode of administration and the therapeutic application. Optimal dosage, frequency, length and modes of administration for an individual patient can readily be determined by conventional protocols, known to those skilled in the art.
It is understood that the dosage of the compound in Sequence Group A, B, or C, fragment, analog and derivative thereof administered in vivo or in vitro will be dependent upon the age, sex, health, and weight of the recipient, type of concurrent treatment if any), frequency of treatment, and the nature of the effect desired. The most preferred dosage will be tailored to the individual subject, as is understood and determinable by one of skill in the art, without undue experimentation.
A typical regimen for preventing, suppressing or treating pathologies, such as Alzheimer's disease amyloidosis, comprises administration of an effective amount of compound in Sequence Group A, B, or C, fragment, analog or derivative thereof, administered over a period of one to several days, up to and including between one week and about 72 months.
The total dose required for each treatment may be administered in multiple doses or in a single dose. A compound in Sequence Group A, B, or C, fragment, analog and derivative thereof may be administered alone or in conjunction with other therapeutics directed to pathologies, such as Alzheimer's disease or other Aβ amyloid diseases, as described herein.
Effective amounts of a compound in Sequence Group A, B, or C, fragment, analog and derivative thereof, are about 0.01 μg to about 100 mg/kg body weight, and preferably from about 10 μg to about 50 mg/kg body weight, such as 0.05, 0.07, 0.09, 0.1, 0.5, 0.7, 0.9, 1, 2, 5, 10, 20, 25, 30, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 mg/kg.
Pharmaceutical compositions comprising at least one Sequence Group A, B, or C compound or anti-idiotypic antibody may also include suitable solutions for administration intravenously, subcutaneously, dermally, nasally, orally, mucosally, rectally or may by injection or orally, and contain from about 0.01 to 99 percent, preferably about 20 to 75 percent of active component i.e. peptide or antibody) together with the excipient. Pharmaceutical compositions for oral administration include pills, tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixers, suspensions, emulsions, solutions, and syrups.
The Sequence Group A, B, or C compound, fragment, analog and derivative thereof for the treatment of Alzheimer's disease and other central nervous system Aβ amyloidoses may be modified to cross the blood-brain barrier. Various modifications known in the art for increasing transport across the blood-brain-barrier for reviews of such modifications, see e.g. Pardridge W. M. 1994) Trends in Biotechnol. 12:239-245; Van Bree, J. et al 1993) Pharm World Sci. 15:2-9; and Pardridge W. M. 1992) Pharmacol. Toxicol. 71:3-10). One approach is to increase the lipophilicity log P) of the peptide by covalent linking of the amino or carboxyl terminal to a fatty acid or acyl group such as acetyl) as was done in some of Sequence Group A, B, or C peptides. Another approach is to conjugate the peptide to a protein that normally undergoes absorptive mediated transcytosis or receptor mediated transcytosis through the blood-brain-barrier. These proteins include ligands for brain capillary endothelial receptors such as a monoclonal antibody to the transferrin receptor, histones, biotin, folate, niacin, panthothenic acid, or glycopeptides. Another approach is to link the peptide to a highly positively charged compound as were done in some of the Sequence Group A, B, and C peptides) such as lysine, polylysine, arginine, polyarginine, lysine-arginine peptide, putrescine, spermidine, spermine, etc, all of which are known to facilitate crossing through the blood-brain-barrier presumably by binding to a receptor.
Another approach to enhance blood-brain-barrier transport of peptides is by encapsulation into a carrier vector such as liposome or polymeric microspheres, preferably positively charged for the same reason as described above. The carrier vector can also be modified to target blood-brain-barrier transport receptors, such as the transferrin receptor, by linking the peptide, for example, to an antibody against the transferrin receptor.
Another approach is to co-administer the peptide with agents that permeabilize the blood-brain-barrier, such as bradykinin or a bradykinin agonist.
The blood-brain-barrier permeable drug is a desirable characteristic of central nervous system drugs in general. However, the disclosed embodiments do not necessarily have to fulfill blood-brain-barrier permeability requirements in order to fulfill intended purposes i.e., effective treatment of Alzheimer's disease and other amyloidosis). Peripheral sequestration of Aβ by Sequence Group A, B, or C compounds, fragments, analogs, derivatives thereof, and anti-idiotypic antibodies will result in movement of Aβ from the brain to the peripheral circulation, depleting brain Aβ, inhibiting brain Aβ amyloid fibril formation, and/or causing dissolution of pre-formed brain Aβ amyloid fibrils. This is due to the fact as demonstrated in the previous studies that Aβ freely crosses the blood-brain-barrier Poduslo et al., Neurobiol. Dis. 4:27-34, 1997; Ghilardi et al., Neuroreport 17:2607-11, 1996; Pluta et al., Neuroreport. 7:1261-51996, 1996; Zlokovic, Neurobiol Dis. 4:23-6, 1996).
The Sequence Group A, B, or C compound, fragment, analog and derivative thereof for the treatment of Alzheimer's disease and other central nervous system Aβ amyloidoses may be administered in various ways. Methods of administration include but are not limited to systemic administration, parenteral administration i.e., via an intraperitoneal, intravenous, perioral, subcutaneous, intramuscular, intraarterial, intradermal, intramuscular, intranasal, epidural or oral routes. In a preferred embodiment, Sequence Group A, B, or C compound, fragment, analog and derivative thereof may be directly administered to the cerebrospinal fluid by intraventricular injection. In a specific embodiment, it may be desirable to administer Sequence Group A, B, or C compound, fragment, analog and derivative thereof locally to the area or tissue in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, by injection, by infusion using a cannulae with an osmotic pump, by means of a catheter, by means of a suppository, or by means of an implant.
In yet another embodiment Sequence Group A, B, or C compound, fragment, analog and derivative thereof may be administered in a controlled release system, such as a well-calibrated osmotic pump. In yet another embodiment, a controlled release system can be placed in proximity to the therapeutic target, i.e. the brain, thus requiring only a fraction of the systemic dose.
In yet another aspect, peptidomimetic compounds modeled from Sequence Group A, B, or C peptides identified as binding Aβ or other amyloid proteins, serve as potent inhibitors of amyloid formation, deposition, accumulation and/or persistence in Alzheimer's disease and other Aβ amyloidoses. Peptidomimetic modeling is implemented by standard procedures known to those skilled in the art. These peptidomimetic compounds may be administered with formulations, dosages, frequencies, lengths, and routes as outlined above, for the therapeutic purpose of treating Aβ amyloidosis.
Diagnostic Applications
In disclosed methods, Aβ amyloid can be contacted with a disclosed peptide either in vitro or in vivo. Thus the term “contacted with” is intended to encompass both incubation of the peptide and anti-idiotypic antibodies with Aβ amyloid preparation in vitro and delivery of the peptide and anti-idiotypic antibodies to a site in vivo where Aβ amyloid is present. Since the peptides and anti-idiotypic antibodies interact with Aβ amyloid, they can be used to detect Aβ amyloid, either in vitro or in vivo. Accordingly, the compounds can also be used as diagnostic agents to detect the presence or absence of Aβ amyloid in a biological sample or in vivo in a subject. Furthermore, detection of Aβ amyloid using the compounds can be used to diagnose Aβ amyloidosis in a subject.
In one embodiment, a compound is used in vitro to detect and quntitate Aβ amyloid in sample such as cerebrospinal fluid from AD patient, suspected AD patient, a person with a family history of AD, or a normal adult). To aid in detection, the compound can be modified with a detectable substance. The Aβ amyloid in the sample can be immobilized and the compound with the detectable substance is contacted with the immobilized Aβ amyloid or sample, such as in tissue sections. The remaining unbound compound is removed and the compound bound to Aβ can be detected. Alternatively, the unbound compound which is inversely proportional to the bound compound and hence amount of Aβ in the sample can be detected by various means, such as mass spectrometry and other spectrometric determinations including fluorescence, phosphorescence, and, absorbance of various wavelengths of light from UV to infrared, all the way down to radiowaves such as that for NMR. For example, the detectable substance can be biotin i.e. an amino-terminally biotinylated Sequence Group A, B, or C peptide) that can be detected using enzyme labeled avidin. The enzyme, in turn, when later exposed to an appropriate substrate, will react with the substrate in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric, or by visual means. Enzymes which can be used detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colometric methods which employ a chromogenic substrate for the enzyme. Detection can be accomplished by colometric methods which employ a chromogenic substrate for the enzyme. Detection can also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate with similarly prepared standards see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory 1988; Ausubel et al, eds., Current Protocols in Molecular Biology, Wiley Interscience, N.Y. 1987, 1992).
Selected disclosed compounds may also be used to quantitatively or qualitatively detect Aβ amyloid in a biological sample. This can be accomplished by immunofluorescence techniques employing a fluorescently labeled disclosed compound coupled with light microscopic, flow cytometric or fluorometric detection.
Detection may be accomplished using any of a variety of other immunoassays. For example, by radiolabeling of the compound. A good description of this assay may be found in Laboratory Techniques and Biochemistry in Molecular Biology, by Work et al, North Holland Publishing Company, NY 1978) with particular reference to the chapter entitled “An Introduction to Radioimmune Assay and Related Techniques” by Chard, incorporated entirely by reference herein. The radioactive isotope can be detected by such means as the use of a gamma-counter, a scintillation counter or by autoradiography.
It is also contemplated to label the compound with a fluorescent compound. When the fluorescently labeled compound is exposed to light of the proper wavelength, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine, that are commercially available, e.g., from Molecular Probes, Inc. Eugene, Oreg., U.S.A.).
Compounds can also be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged compound is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent labeling compounds are luminol, isoluminol, theromatic acridinium ester, imidazole, acridinium salt, and oxalate ester.
Likewise, a bioluminescent compound may be used to label the compound. Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, lucifers and aequorin.
Compounds may also be used histologically, as in immunofluorescence or immunoelectron microscopy, for in situ detection of Aβ amyloid. Removing a histological specimen from a patient, and providing the labeled compound to such a specimen may accomplish in situ detection. The compound is preferably provided by applying or by overlaying the labeled compound or fragment) to a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of Aβ amyloid but also its distribution in the examined tissue. Thus, those of ordinary skill will readily perceive that any of a wide variety of histological methods such as staining procedures) can be modified in order to achieve such in situ detection.
Compounds which interact with Aβ, or derivatives thereof are also disclosed herein. The compounds can be used for a number of important diagnostic and/or therapeutic applications as described herein. In one aspect, peptides which bind Aβ may be utilized for ligand blot analysis using standard ligand blotting techniques known to those skilled in the art) to detect the presence of Aβ amyloid protein fragments in human tissues and in tissues of other species. Ligand blot analysis can also be used to determine the apparent size of each amyloid protein fragment. In addition, ligand blotting followed by scanning densitometry known to those skilled in the art) can be used to quantitate and compare levels of each of the peptides in tissue samples, biological fluids or biopsies obtained from individuals with specific diseases such as the amyloid diseases) in comparison to tissue samples, biological fluids or biopsies obtained from normal individuals or controls. Biological fluids, include, but are not limited to, blood, plasma, serum, cerebrospinal fluid, sputum, saliva, urine and stool.
In another embodiment, a compound is used in vivo to detect, and if desired, quantitate, Aβ amyloid deposition in a subject, for example, to aid in the diagnosis of Aβ amyloidosis in the subject. To aid in detection, the compound can be modified with a detectable substance, preferably 99mTc or radioactive iodine. Methods for labeling peptide compounds with technetium are known in the art. A modifying group can be chosen that provides a site at which a chelation group for 99mTc can be introduced, such as a derivative of cholic acid, which has a free amino group. Also provided are Sequence Group A, B, or C peptides labeled with radioactive iodine through their aromatic amino acid, either already present or incorporated, for the purpose of labeling. Any of the various isotopes of radioactive iodine can be incorporated to create a diagnostic agent. Preferably, 123I half-life=13.2 hrs) can be used for whole body scintigraphy, 124I half-life=4 days) or 13F for positron emission tomography PET), 125I half-life=60 days) for metabolic turnover studies, and 131I half-life=8 days) for whole body counting and delayed low resolution imaging studies.
In compliance with the statute, the invention has been described in language more or less specific as to structural features. It is to be understood, however, that the invention is not limited to the specific features shown, since the means and construction shown comprise preferred forms of putting the invention into effect. The invention is, therefore, claimed in any of its forms or modifications within the legitimate and valid scope of the appended claims, appropriately interpreted in accordance with the doctrine of equivalents.
Castillo, Gerardo, Snow, Alan D., Lake, Thomas, Hu, Qubai, Sanders, Virginia, Nguyen, Beth, Cam, Judy A.
| Patent | Priority | Assignee | Title |
| 10463745, | May 12 2015 | Northwestern University | Materials for tissue regeneration |
| 10882890, | Jul 25 2014 | Academia Sinica | Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates |
| Patent | Priority | Assignee | Title |
| 5948763, | Jun 06 1995 | New York University | Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits |
| WO134631, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Nov 26 2008 | PROTEOTECH INC. | (assignment on the face of the patent) | / | |||
| Jan 05 2009 | NGUYEN, BETH | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024279 | /0488 | |
| Jan 23 2009 | HU, QUBAI | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024279 | /0017 | |
| Jan 23 2009 | CAM, JUDY A | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024279 | /0108 | |
| Jan 24 2009 | CASTILLO, GERARDO | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024277 | /0791 | |
| Jan 27 2009 | SNOW, ALAN D | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024279 | /0292 | |
| Jan 27 2009 | LAKE, THOMAS P | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024279 | /0343 | |
| Apr 15 2010 | SANDERS, VIRGINIA | Proteotech Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 024279 | /0511 |
| Date | Maintenance Fee Events |
| Feb 23 2015 | M2551: Payment of Maintenance Fee, 4th Yr, Small Entity. |
| Apr 15 2019 | REM: Maintenance Fee Reminder Mailed. |
| Sep 30 2019 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Aug 23 2014 | 4 years fee payment window open |
| Feb 23 2015 | 6 months grace period start (w surcharge) |
| Aug 23 2015 | patent expiry (for year 4) |
| Aug 23 2017 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Aug 23 2018 | 8 years fee payment window open |
| Feb 23 2019 | 6 months grace period start (w surcharge) |
| Aug 23 2019 | patent expiry (for year 8) |
| Aug 23 2021 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Aug 23 2022 | 12 years fee payment window open |
| Feb 23 2023 | 6 months grace period start (w surcharge) |
| Aug 23 2023 | patent expiry (for year 12) |
| Aug 23 2025 | 2 years to revive unintentionally abandoned end. (for year 12) |